. 2021 Oct 7;3(4):otab071. doi: 10.1093/crocol/otab071

Table 2.

Results of waste analysis for both the real-world analysis (N = 1003 administrations of infliximab) and the ideal, weight-based analysis (N = 413 IBD patients’ presenting weights).

		Real-world analysis (N = 1003)			Ideal, weight-based analysis (N = 413)
Infliximab vial size		100 mg^a	50 mg^b	25 mg^b	100 mg^a	50 mg^b	25 mg^b
Quantity of drug waste per administration, mean ± SD		17.3mg ± 24.6	1.4mg ± 5.8	0.1mg ± 1.4	49.5mg ± 28.2	24.6mg ± 14.3	12.2mg ± 6.8
Financial value of drug waste per administration, mean ± SD	Medicare Part B Average Sales Price²⁵	$112.40 ± $159.76	$8.78 ± $37.59	$0.68 ± $8.86	$321.50 ± $183.01	$159.50 ± $92.73	$79.28 ± $44.46
Financial value of drug waste per administration, mean ± SD	Average Wholesale Price²⁶	$242.48 ± $344.66	$18.93 ± $81.08	$1.47 ± $19.11	$693.58 ± $394.81	$344.08 ± $200.04	$171.03 ± $95.91
Potential waste reduction from current 100mg vials (%)		x	92.2%	99.4%	x	50.4%	75.3%

Currently manufactured vial size

Theoretical vial sizes.